{
  "id": 13937318,
  "title": "Guggenheim reiterates LB Pharmaceuticals stock rating on study data",
  "url": "https://urgent.news/2026/10/12/guggenheim-reiterates-lb-pharmaceuticals-stock-rating-on-study-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T10:58:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-lb-pharmaceuticals-stock-rating-on-study-data-93CH-4943965"
  },
  "original_language": "en",
  "account": null,
  "summary": "Guggenheim reiterated a Buy rating and $80.00 price target on LB Pharmaceuticals Inc (NASDAQ:LBRX) following new preclinical study results. The study presented at the ECNP congress provides direct functional evidence that orally administered LB-102 engages presynaptic dopamine D2/D3 autoreceptors in the rat nucleus accumbens. This confirms the mechanistic premise of the bimodal dose thesis underpinning the multi-indication model, supporting ongoing trials for bipolar depression and major depressive disorder. LB Pharmaceuticals has seen a surge in activity surrounding its lead drug candidate, LB-102, with various analysts expressing confidence in the company's pipeline and potential future indications.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}